What it is
L-carnitine is a nutrient-derived molecule involved in mitochondrial fatty-acid transport.
Evidence boundary
L-carnitine use depends on indication and deficiency state. Do not generalize body-composition claims from one setting to every setting.
Preparation and measurement
Reconstitution: 200 mg vial + 2 mL BAC = 100 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 | 50 mg | 0.50 mL of 100 mg/mL solution | Once daily | 350 mg/week |
| Weeks 3–12 | 100 mg | 1.00 mL of 100 mg/mL solution | Once daily | 700 mg/week |
| Upper source variant | 200 mg | 2.00 mL of 100 mg/mL solution | Once daily | 1,400 mg/week |
Weeks 1–2
- Dose
- 50 mg
- Draw / measure
- 0.50 mL of 100 mg/mL solution
- Frequency
- Once daily
- Weekly total
- 350 mg/week
Weeks 3–12
- Dose
- 100 mg
- Draw / measure
- 1.00 mL of 100 mg/mL solution
- Frequency
- Once daily
- Weekly total
- 700 mg/week
Upper source variant
- Dose
- 200 mg
- Draw / measure
- 2.00 mL of 100 mg/mL solution
- Frequency
- Once daily
- Weekly total
- 1,400 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Daily titration (subcutaneous):
-
Weeks 1–2 (titration): 50 mg/day. Assess injection-site tolerance.
-
Weeks 3–12 (target): 100 mg/day. 100 mg = 1.0 mL exactly at 100 mg/mL concentration.
-
Advanced (optional): Up to 200 mg/day for robust experimental protocols. Split into 2 injections at different sites.
-
Cycle: 8–12 weeks; optional extension to 16 weeks.
-
Timing: Once daily at any consistent time; morning or pre-exercise commonly used.
-
Tolerability and injection-site comfort if using parenteral forms
-
Indication-specific outcome data
Practical rules
- Keep it separate from peptide stacks.
- Use indication-specific evidence, not general fat-loss hype.
- Rotate sites if parenteral use is being compared.